All Takeda articles
-
News
Why jury verdicts get overruled in US industry cancer trials
Judges often end up intervening post-trial in complex cases with conflicting scientific evidence
-
Business
Pharmaceuticals roundup 2018
Merger deals, product approvals and infrastructure changes have been overshadowed by political uncertainty, in Europe and around the world
-
Business
Novartis to cut over 2000 jobs
Move exemplifies a wave of manufacturing cuts as pharma moves to more high-value, specialised medicines
-
Business
Takeda set to swallow Shire
Shire’s US revenue and rare diseases portfolio grab Japanese firm’s attention
-
Business
Dementia slips down pharma agenda
Pfizer, Shire, Acorda and Axovant rethink their neuroscience strategies
-
Business
Takeda tightens focus on core areas with multiple deals
Japanese firm is remodelling its R&D efforts through collaboration and licensing deals, and selling off non-core businesses
-
Business
Job cuts at Amgen, Takeda and Vertex
Takeda reorganising following Ariad takeover, while Amgen and Vertex move staff to Cambridge and San Francisco hubs
-
Business
Takeda to buy cancer specialist Ariad
Japan’s largest drug company agrees $5.2bn deal to expand oncology portfolio and boost pipeline
-
Business
Job cuts at Takeda, Boehringer and Arena
Hundreds of positions eliminated as companies re-evaluate R&D
-
Business
Takeda to consolidate vaccines business in Boston
Firm will close three recently-acquired US sites and shift operations to the growing pharmaceutical hub in Massachusetts
-
Business
Takeda offers $2.4bn to settle diabetes litigation
Aims to settle multiple outstanding lawsuits relating to Actos (pioglitazone) and bladder cancer
-
Business
Judge slashes fines in drug safety case
Takeda and Eli Lilly’s $9 billion damages in diabetes trial reduced to $38 million
-
Business
Affymax folds after drug withdrawal
Unexplained allergic reactions to anaemia drug prompt firm to dissolve
-
Business
Missing safety risk emails draw $9bn Actos fine
Judge finds absence of Takeda documentation in bladder cancer case ‘disturbing’
-
Business
Lundbeck cuts jobs in Europe, but expands in US
Depression drug approval fuels US recruitment
-
Business
Pfizer and Takeda win $2.15bn in patent payout
Teva and Sun fined for selling generics before patent expiry
-
Business
Japanese pharma opens compound vaults
Molecule libraries to be screened for neglected diseases
-
Business
Judge reverses jury decision over $6.5m Takeda payout
Not enough evidence to link diabetes drug to bladder cancer, the company claims